SecBot SecBot

LGND drug pipeline

$308.79
−2.4% 1-day · Nov 13
Next catalyst
Feb 28, 2027
Qtorin rapamycin PDUFA date · in 104 days
Typical move on FDA news
±3.1%
1-day, median of 6 events
IV rank
No data
No current options data
Rated drugs
6
1 bearish · 5 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

1 dated
  1. Feb 28, 2027104d
    Qtorin rapamycin
    PDUFA date · microcystic lymphatic malformations

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3
Time to marketIf the full upLIFT results (expected mid-December 2026) remain positive, Rezolute could file a Biologics License Application (BLA) for tumor hyperinsulinism in 2027. The congenital HI path is less clear after the sunRIZE miss, though the FDA has recommended a pre-BLA meeting. Analyst projections from 2025 suggested a potential market launch in 2027 for at least one indication.

Ersodetug Updated Nov 13

What to watch

The next hard catalyst for ersodetug is the full topline results from the Phase 3 upLIFT study in tumor HI, expected by mid-December 2026. Positive results would support a BLA filing for tumor HI, while the congenital HI path remains uncertain after the sunRIZE miss. For LGND holders, this is a minor portfolio contributor; for RZLT holders, it is the primary value driver.

Bull case
  • The Phase 3 upLIFT study in tumor hyperinsulinism met its primary efficacy endpoint, with 13 of 16 participants achieving the response criterion.
  • Ersodetug has both FDA Breakthrough Therapy Designation and Orphan Drug Designation for tumor HI, which could accelerate development and review.
  • Through the XOMA acquisition (closed July 2026), Ligand holds high-single to mid-teen percentage royalty rights on any future ersodetug sales.
Bear case
  • The Phase 3 sunRIZE study in congenital hyperinsulinism failed its primary endpoint in December 2025, leaving the regulatory path for that larger indication unresolved.
  • Rezolute priced a $100M stock offering concurrently with the positive upLIFT news, diluting existing shareholders.
  • Tumor hyperinsulinism is an ultra-rare condition with limited commercial upside; peak sales estimates for ersodetug are only around $300M.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the US (since 2022), EU (Immedica became MAH in June 2025), and China (approved 2024). No new approval decision is pending.

ganaxolone Updated Oct 29

What to watch

No near-term binary catalyst exists for ganaxolone affecting LGND. Immedica (private) plans to launch a new Phase 3 study of IV ganaxolone in refractory status epilepticus in 2027, but this is several years from any commercial outcome and Ligand's Captisol exposure is small. Watch Immedica's commercial execution for Ztalmy and any label expansions, but none are likely to move LGND stock materially.

Bull case
  • Ztalmy is the only FDA-approved treatment for CDKL5 deficiency disorder, a rare pediatric epilepsy with no other approved therapies, giving it a strong market position
  • Three-year efficacy data presented at EEC 2026 showed sustained benefit in CDD patients, supporting long-term use
  • Label update in Dec 2025 with a 28-day titration schedule improved convenience for patients and prescribers
Bear case
  • Phase 3 trials in tuberous sclerosis complex (TrustTSC) and refractory status epilepticus (RAISE) both failed or missed key endpoints, casting doubt on pipeline expansion beyond CDD
  • NCE-1 exclusivity expired in March 2026, opening the door to patent challenges (first eligible June 2026), though patents may protect until ~2042
  • Ztalmy's CDD indication targets an extremely small patient population, limiting peak revenue potential
▼ bearish
Impact
PhaseApproved (EU/UK/Japan); Filed/PDUFA review in US
Time to marketAlready marketed in the EU (European Commission approval June 2025) and UK (MHRA approval) under Santen's commercial operations. Launched in Japan as RYJUSEA in April 2025. US approval timeline uncertain after the CRL and pending tomorrow's AdComm.

Ryjunea atropine sulfate Updated Oct 29

What to watch

The FDA Dermatologic and Ophthalmic Drugs Advisory Committee meets October 30, 2026 to review SYD-101/Ryjunea for US approval. FDA briefing documents released October 28 question the drug's efficacy at slowing myopia progression. An unfavorable AdComm vote would likely keep Ryjunea out of the US market indefinitely; a favorable vote would still face an FDA decision. For LGND this catalyst matters less than for Sydnexis since Ligand holds only EMEA royalty rights.

Bull case
  • Ryjunea is the first and only approved pharmacologic treatment in the EU and UK for slowing pediatric myopia, addressing a large and growing global market (myopia projected to affect half the world by 2050).
  • The Phase 3 STAR trial met its primary efficacy endpoint, and subgroup analyses presented at AAPOS 2026 showed benefit particularly in fast progressors.
  • Ligand paid only $23M upfront for the EMEA royalty stream, a small outlay for potential decades of tiered low-double-digit to high-teens royalties with no further development cost.
Bear case
  • FDA briefing documents released October 28, 2026 question whether SYD-101 is effective at slowing myopia, and the agency already issued a Complete Response Letter in October 2025 citing insufficient evidence of efficacy despite the STAR trial meeting its primary endpoint.
  • The FDA Advisory Committee vote tomorrow could be negative, effectively blocking US approval and limiting Ryjunea's commercial opportunity to the smaller EMEA market where Santen handles commercialization.
  • Competing low-dose atropine programs (Vyluma's NVK002) also received FDA CRLs, suggesting the agency has a high bar for atropine in myopia and may require additional large trials.
● neutral
Impact
PhasePhase 1b (dose expansion)
Time to marketLikely several years away, if successful. AVC-201 is currently in Phase 1b expansion; a registrational Phase 2/3 trial would follow before any regulatory filing.

AVC-201 allo-revcar01-t-cd123 Updated Oct 29

What to watch

Watch for Phase 1b expansion interim data from the RevSTAR-123 study, which could come in 2027 at a major medical congress (ASH, EHA). If the dose-dependent efficacy signal holds in a larger cohort with manageable safety, it would strengthen the thesis for AVC-201's registrational potential. However, Ligand's stock will be far more influenced by its Q3 2026 earnings (reported today, Oct 29), guidance, and commercial royalty performance than by any AvenCell news in the near term.

Bull case
  • Phase 1a results showed a clean safety profile (no GvHD, no neurotoxicity, mostly low-grade CRS) in a very sick AML population, which compares favorably to autologous CAR-T approaches
  • Dose-dependent activity at higher dose levels produced 3 CR/CRh among 8 evaluable patients, including 2 MRD-negative conversions, suggesting real anti-leukemic efficacy
  • The allogeneic off-the-shelf design could address key CAR-T commercialization challenges: no patient waiting time, lower manufacturing cost, and controllable on/off activity
Bear case
  • AVC-201 is in Phase 1b with no registrational trial started yet; AML is a notoriously difficult indication and many promising early-stage cell therapies have failed in later trials
  • The Phase 1a sample size (n=17) is very small and response rates could shrink in larger, more diverse populations
  • Competition in CD123-targeted AML cell therapy is intensifying, with multiple autologous and allogeneic programs from larger companies
● neutral
Impact
PhasePhase 3 (completed; results missed primary endpoints)
Time to marketUncertain and distant: the drug failed Phase 3 and is being restarted by a private company that has not disclosed its clinical development timeline or regulatory strategy.

soticlestat Updated Oct 29

What to watch

Ligand holds a passive 13% royalty/milestone interest in soticlestat, a drug that failed Phase 3 trials and was abandoned by Takeda before being revived by a private Perceptive Advisors-backed NewCo in August 2026. There is no near-term binary catalyst for this asset; the new private sponsor has not disclosed its clinical timeline. For LGND investors, soticlestat is a tail-risk option on a revived program, not a core value driver.

Bull case
  • The Phase 3 SKYLINE study narrowly missed its primary endpoint (p=0.06) and showed statistically significant results in several key secondary efficacy endpoints, suggesting the mechanism may still be viable with a better trial design.
  • Perceptive Advisors, a sophisticated life sciences investor, chose to back the asset, signaling that it believes the FDA's concerns were about trial design flaws rather than the drug's underlying mechanism or safety profile.
  • The drug retains FDA orphan drug designations for both Dravet syndrome and Lennox-Gastaut syndrome, which provide market exclusivity and development incentives if ultimately approved.
Bear case
  • Soticlestat failed both Phase 3 SKYLINE (Dravet syndrome) and SKYWAY (Lennox-Gastaut syndrome) trials, missing primary endpoints in June 2024, leading Takeda to discontinue the program in January 2025 after the FDA flagged data shortcomings.
  • A 2026 structure-activity relationship study in the journal Molecules noted that soticlestat suffers from 'unsatisfactory in vivo potency' in animal models and clinical trials, raising questions about the drug's fundamental profile.
  • The drug is now controlled by a private company with no disclosed clinical development timeline or funding details, making the path to potential milestone payments highly uncertain and distant.
● neutral
Impact
PhasePhase 1/2
Time to marketLikely years away. The QUADvance Phase I/II trial's primary completion is estimated for April 2029. Even with potential accelerated development, regulatory filing would be at least several years away given the Phase 1a dose-escalation stage.

AVC-203 Allo-QuadCAR01-T Updated Oct 29

What to watch

AVC-203 is in very early clinical testing (Phase 1a dose escalation), with no hard-dated binary catalysts on the horizon. The primary completion of the QUADvance study is estimated for April 2029. For LGND investors, this program is a minor, early-stage royalty interest among over 200 assets in Ligand's portfolio; watch for any early Phase 1a data disclosures at medical meetings, but the near-term stock thesis for LGND is determined by its established royalty portfolio and earnings trajectory, not this single program.

Bull case
  • AVC-203 is the first CRISPR-engineered allogeneic dual-targeting CD19/CD20 switchable CAR-T to enter clinical testing, combining dual antigen targeting (to reduce relapse via antigen escape), immune-evasive engineering, and off-the-shelf convenience.
  • The dual-targeting CD19/CD20 approach addresses a key limitation of single-target CD19 CAR-Ts (relapse due to CD19 loss), and the allogeneic 'off-the-shelf' format could improve patient access vs. expensive, logistically complex autologous CAR-Ts.
  • Regulatory momentum is positive: both FDA (IND clearance) and EMA (CTA approval) allowed the QUADvance trial to proceed, and the first patient was dosed in April 2026, just 4 months after regulatory clearance.
Bear case
  • Allogeneic CAR-T is a technically challenging field; several competitors have faced safety (cytokine release syndrome, neurotoxicity) and efficacy (persistence, rejection) hurdles in early trials.
  • AVC-203 faces intense competition from approved autologous CD19 CAR-Ts (Kymriah, Yescarta, Tecartus, Breyanzi) and other allogeneic programs from Allogene Therapeutics, Caribou Biosciences, and CRISPR Therapeutics.
  • The QUADvance Phase I/II study has an estimated primary completion date of April 2029; meaningful clinical data will take years, and early-stage cell therapy trials have a high attrition rate.

Other drugs in filings and trials

no drug report yet
  • Qtorin rapamycin Next: PDUFA date · Feb 28, 2027
  • Filspari Last: Approval · Aug 6, 2026
  • Tzield Last: PDUFA decision · Apr 29, 2026

Past FDA events & how the stock moved

6 events
DateDrugEvent1 day5 days
Aug 6, 2026FilspariApproval−3.1%−4.5%
Apr 29, 2026TzieldPDUFA decision−1.2%+0.1%
Apr 29, 2026TzieldPriority review−1.2%+0.1%
Apr 13, 2026FilspariApproval+13.4%+13.1%
Apr 13, 2026FILSPARIPDUFA decision+13.4%+13.1%
Jan 5, 2026TzieldPriority review+3.1%+8.8%